ScoreComparison
Why is Allogene Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate 3.69% of over the last 5 years
2
With a growth in Net Sales of INF%, the company declared Very Positive results in Jun 26
- OPERATING CASH FLOW(Y) Highest at USD -102.2 MM
- NET PROFIT(HY) Higher at USD -85.28 MM
- ROCE(HY) Highest at -42.39%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 46.15%, its profits have risen by 22.1%
4
High Institutional Holdings at 81.13%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 46.15% in the last 1 year, much higher than market (S&P 500) returns of 16.00%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Allogene Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Allogene Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Allogene Therapeutics, Inc.
42.74%
-0.35
86.28%
S&P 500
15.76%
1.22
13.15%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
3.69%
EBIT to Interest (avg)
-269.24
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.71
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.03%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.88
EV to EBIT
-1.49
EV to EBITDA
-1.59
EV to Capital Employed
6.11
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-409.44%
ROE (Latest)
-64.44%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -102.2 MM
NET PROFIT(HY)
Higher at USD -85.28 MM
ROCE(HY)
Highest at -42.39%
RAW MATERIAL COST(Y)
Fallen by -4,300% (YoY
NET SALES(9M)
Higher at USD 4.64 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 2.38 times
EPS(Q)
Highest at USD -0.13
-5What is not working for the Company
INTEREST(HY)
At USD 0.64 MM has Grown at 53.83%
Here's what is working for Allogene Therapeutics, Inc.
Net Sales
At USD 4.64 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -102.2 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD -85.28 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -0.13
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 2.38 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Higher at USD 4.64 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by -4,300% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Allogene Therapeutics, Inc.
Interest
At USD 0.64 MM has Grown at 53.83%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Footer loading
